Clinical Trials Browser

Lymphoma, Large-Cell, Anaplastic × Crizotinib × Clear all

NCT05160922 2025-09-03

Crizotinib Continuation Clinical Study

Phase 4 Active not recruiting

LymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic

NCT01606878 2024-01-05

Crizotinib and Combination Chemotherapy in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Phase 1 Completed

46 enrolled 24 charts

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

NCT01524926 2023-12-11

CREATE

Phase 2 Completed

LymphoidPlasma cellSarcoma

Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Sarcoma, Clear Cell, Rhabdomyosarcoma, Alveolar, Sarcoma, Alveolar Soft Part

NCT02419287 2023-03-06

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Phase 2 Completed

Lymphoma, Large-Cell, Anaplastic

NCT00939770 2020-06-09

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

Phase 1/2 Completed

122 enrolled 24 charts 2 FDA

Neuroblastoma, Lymphoma, Large-Cell, Anaplastic

NCT02487316 2016-12-30

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Phase 4 Withdrawn

Lymphoma, Large-Cell, Anaplastic